Catalyst
Slingshot members are tracking this event:
Beigene's(BGNE) Phase 1b data of Zanubrutinib and Obinutuzumab in Relapsed/Refractory Follicular Lymphoma to be presented at ICML
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BGNE | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 20, 2019
Occurred Source:
http://ir.beigene.com/news-releases/news-release-details/beigene-announces-phase-1b-clinical-results-zanubrutinib
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Zanubrutinib, Obinutuzumab
